Skip to content
Library/For Energy/Tesamorelin
FDA-approved (Egrifta)⚠ WADA-banned✓ Free to read

Tesamorelin

The deep fat wrapped around your organs is the target, and it is FDA-approved to shrink exactly that, not the fat you can pinch.

Updated 19 May 2026Read 3 minBacked by 60 studies
The quick version
What it is
A daily shot that copies a natural growth-hormone signal (brand: Egrifta SV)
Is it FDA-approved?
Yes, but only for HIV-related belly fat (lipodystrophy)
How strong is the proof?
Strong. Two Phase 3 trials, the best-studied drug in its family
How you take it
A shot under the skin, daily
Typical result
About 15-18% drop in deep organ fat at 26 weeks
Biggest catch
It does NOT touch the belly fat you can pinch. Brand is very expensive

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

Tesamorelin is a daily shot. It is a stronger, more stable version of the natural hormone GHRH. The brand name is Egrifta SV.

Like sermorelin, it tells your body to release more of its own growth hormone. But it is more powerful and far better studied.

It got FDA approval in 2010, but only for one thing: a kind of belly fat seen in people with HIV (called lipodystrophy).

A key fact: it shrinks visceral fat, the fat deep around your organs. It does not shrink the fat you can pinch with your fingers.

What people use it for.

The approved use is the deep belly fat that some people with HIV get.

Off-label, doctors use it for visceral fat in middle-aged adults, and some study it for fatty liver disease.

If you want to lose the love handles or the lower-belly pooch you can see in the mirror, this is the wrong tool. That is fat, and tesamorelin barely touches it.

Does it actually work?

Yes, for what it actually does. This is the best-studied drug in its family.

Two Phase 3 trials in HIV patients showed about 15-18% less visceral fat at 26 weeks, measured on a CT scan. Later trials showed it can lower liver fat too.

But "works" means it shrinks the deep, hidden fat. The fat you can pinch barely moves. If a clinic sells it for love handles, they are misusing the approval.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

Tesamorelin actually works to shrink belly fat.

true

This is the best-studied drug in its family. Two Phase 3 trials showed about 15 to 18% less visceral fat at 26 weeks, measured on a CT scan. That part is the real deal.

It melts the belly fat you can pinch in the mirror.

no

It shrinks the deep fat wrapped around your organs, not the soft fat you can pinch. That pinchable fat barely moves. If a clinic sells it for love handles, they are misusing the approval.

It is a general weight-loss drug.

not quite

It is only for one thing: the deep belly fat some people with HIV get. The off-label visceral-fat use is real, but it is not a tool for everyday weight loss the way a shot is.

Cheap research tesamorelin is a steal.

myth

Tesamorelin priced very cheap, around $130 a month or less, is usually mislabeled CJC-1295, a cheaper and shorter molecule. The price is simply too low for the real thing.

How you take it.

You take it as a shot under the skin, usually once a day. People often inject in the belly.

It comes as a freeze-dried () powder you mix with sterile water (). It breaks down fast once mixed, so you keep it cold and use it within about 7-10 days.

A doctor should check your (a growth marker) about every 8 weeks, and stop it if that number climbs too high for your age.

What to watch out for.

The common stuff

Redness or swelling where you inject. Some joint pain, swelling in the hands or feet, or muscle aches.

The serious stuff

  • It raises a growth signal (). Do not use it if you have active or recent cancer.
  • Avoid it with active pituitary disease or severe diabetic eye disease.
  • It can nudge blood sugar up, so people with diabetes need monitoring.
  • It is banned by WADA. Do not use it in a tested sport.

A doctor should track your the whole time. Talk to a real doctor. We are not your doctor.

Where people get it.

From safest to riskiest.

  • Brand (Egrifta SV). The real, tested drug, by prescription. But it is very expensive: about $2,400-$3,100 a month cash. HIV insurance plans often cover it.
  • . Same molecule, made off-label at hormone clinics, about $200-$500 a month. Cheaper, but the FDA oversight stops at the brand.
  • Research-only (). Sold "for research only," about $300-$450 a month. Highest risk. It breaks down fast after mixing.
  • . Overseas raw, around $110-$120 a month.

A red flag: "tesamorelin" priced very cheap (around $130 a month or less) is often mislabeled CJC-1295, a cheaper, shorter molecule. The price is too low for the real thing.

Our honest take.

Of the whole GHRH family, this is the one with the receipts: two Phase 3 trials and real CT-scan proof that it melts the deep fat wrapped around your organs. The catch is in what it does not do, because it leaves the soft fat you can pinch almost untouched. If a scan confirmed that deep fat and a doctor will recheck your every 8 weeks, this is the one setup the data actually supports.

Chasing the pinchable stuff in the mirror? It will not touch that, and it is an expensive way to learn so.

Going ahead means lining up who reads your bloodwork before you start, and pulling the plug the day your climbs past the safe line for your age.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01 Tesamorelin. 2018. PMID: 31644039.
  2. 02Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England). 2024;38(12):1758-1764. PMID: 38905488.
  3. 03Grunfeld C, et al. Tesamorelin. Nature reviews. Drug discovery. 2011;10(2):95-6. PMID: 21283099.
  4. 04O'Neal R. Tesamorelin update. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation. 2010;22(4):16-9. PMID: 21591600.
  5. 05Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-91. PMID: 21668043.
  6. 06Spooner LM, et al. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. The Annals of pharmacotherapy. 2012;46(2):240-7. PMID: 22298602.
  7. 07Wang Y, et al. Tesamorelin, a human growth hormone releasing factor analogue. Expert opinion on investigational drugs. 2009;18(3):303-10. PMID: 19243281.
  8. 08Fourman LT, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight. 2020;5(16). PMID: 32701508.
  9. 09Lake JE, et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England). 2021;35(9):1395-1402. PMID: 33756511.
  10. 10Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2011;25(6):405-8. PMID: 22050344.
  11. 11Ellis RJ, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases. 2025;231(5):1230-1238. PMID: 39813152.
  12. 12Fourman LT, et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports. 2021;11(1):10485. PMID: 34006921.
  13. 13Rahman F, et al. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science. 2022;7(1):e40. PMID: 36845310.
  14. 14Tomlinson B. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Current opinion in investigational drugs (London, England : 2000). 2006;7(10):936-45. PMID: 17086939.
  15. 15Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200.
  16. 16Audsley J, et al. Tesamorelin, liver fat, and NAFLD in the setting of HIV. The lancet. HIV. 2019;6(12):e808-e809. PMID: 31611037.
  17. 17González-Sales M, et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical pharmacokinetics. 2015;54(3):285-94. PMID: 25358450.
  18. 18Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. 2026;54(1):223-229. PMID: 41476424.
  19. 19Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV. 2019;6(12):e821-e830. PMID: 31611038.
  20. 20Fourman LT, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS (London, England). 2017;31(16):2253-2259. PMID: 28832410.
  21. 21Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of clinical endocrinology and metabolism. 2010;95(9):4291-304. PMID: 20554713.
  22. 22Adrian S, et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. The Journal of frailty & aging. 2019;8(3):154-159. PMID: 31237318.
  23. 23Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. PMID: 25038357.
  24. 24Stanley TL, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS (London, England). 2011;25(10):1281-8. PMID: 21516030.
  25. 25Makimura H, et al. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. The Journal of clinical endocrinology and metabolism. 2014;99(1):338-43. PMID: 24178787.
  26. 26McLarnon A. Neuroendocrinology: Tesamorelin can improve cognitive function. Nature reviews. Endocrinology. 2012;8(10):568. PMID: 22926095.
  27. 27Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice. 2026;20(1):2-12. PMID: 41545261.
  28. 28Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012;54(11):1642-51. PMID: 22495074.
  29. 29González-Sales M, et al. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. Journal of pharmacokinetics and pharmacodynamics. 2015;42(3):287-99. PMID: 25895899.
  30. 30Mangili A, et al. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PloS one. 2015;10(10):e0140358. PMID: 26457580.
  31. 31Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of acquired immune deficiency syndromes (1999). 2010;53(3):311-22. PMID: 20101189.
  32. 32Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV/AIDS (Auckland, N.Z.). 2011;3:69-79. PMID: 22096409.
  33. 33Teng S, et al. Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers. Clinical pharmacology in drug development. 2013;2(3):237-45. PMID: 27121785.
  34. 34Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (London, England). 2008;22(14):1719-28. PMID: 18690162.
  35. 35Patel A, et al. Tesamorelin: A hope for ART-induced lipodystrophy. Journal of pharmacy & bioallied sciences. 2011;3(2):319-20. PMID: 21687371.
  36. 36Clemmons DR, et al. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PloS one. 2017;12(6):e0179538. PMID: 28617838.
  37. 37Memdouh S, et al. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug testing and analysis. 2021;13(11-12):1871-1887. PMID: 34665524.
  38. 38Mateo MG, et al. Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy. Expert review of endocrinology & metabolism. 2011;6(1):21-30. PMID: 30764032.
  39. 39 Side effects and complications. Tesamorelin--results from Phase III. TreatmentUpdate. 2007;19(3):6-7. PMID: 17575575.
  40. 40Berger D. Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation. Positively aware : the monthly journal of the Test Positive Aware Network. 2008;19(3):31. PMID: 18724445.
  41. 41Grodeck B. The next generation of human growth hormone. How Serostim and tesamorelin measure up. Positively aware : the monthly journal of the Test Positive Aware Network. 2008;19(5):28-32. PMID: 18828236.
  42. 42Sekhar RV. Treatment of dyslipidemia in HIV. Current atherosclerosis reports. 2015;17(4):493. PMID: 25702057.
  43. 43Traynor K. FDA approves tesamorelin for HIV-related lipodystrophy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2010;67(24):2082. PMID: 21115997.
  44. 44Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine. 2007;357(23):2359-70. PMID: 18057338.
  45. 45Falutz J. Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue. Drugs of today (Barcelona, Spain : 1998). 2011;47(6):419-30. PMID: 21695284.
  46. 46 Side effects and complications. Clinical trials of tesamorelin in Canada. TreatmentUpdate. 2007;19(3):7. PMID: 17571443.
  47. 47Gattu AK, et al. Metabolic dysfunction-associated steatotic liver disease in people with HIV. Current opinion in HIV and AIDS. 2025;20(4):350-358. PMID: 40397552.
  48. 48Fourman LT, et al. Approach to the Patient With Lipodystrophy. The Journal of clinical endocrinology and metabolism. 2022;107(6):1714-1726. PMID: 35137140.
  49. 49Braun LR, et al. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2017;37:1-6. PMID: 29031905.
  50. 50Hussar DA. New drugs 2012, part 2. Nursing. 2012;42(7):38-44; quiz 44-6. PMID: 22692631.
  51. 51Stanley TL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. The Journal of clinical endocrinology and metabolism. 2011;96(1):150-8. PMID: 20943777.
  52. 52Sattler FR. Growth hormone in the aging male. Best practice & research. Clinical endocrinology & metabolism. 2013;27(4):541-55. PMID: 24054930.
  53. 53Vantyghem MC, et al. How to diagnose a lipodystrophy syndrome. Annales d'endocrinologie. 2012;73(3):170-89. PMID: 22748602.
  54. 54Corley MJ, et al. CROI 2024: Neuropsychiatric Complications in People With HIV. Topics in antiviral medicine. 2024;32(4):513-522. PMID: 39746672.
  55. 55Mihalache A, et al. Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study. Cureus. 2025;17(5):e83972. PMID: 40510111.
  56. 56Rochira V, et al. Growth hormone deficiency and human immunodeficiency virus. Best practice & research. Clinical endocrinology & metabolism. 2017;31(1):91-111. PMID: 28477736.
  57. 57Yen DW, et al. Causes and outcomes of hepatic fibrosis in persons living with HIV. Current opinion in HIV and AIDS. 2022;17(6):359-367. PMID: 36165079.
  58. 58Beach R, et al. Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2026;82(Supplement_4):S87-S91. PMID: 42139091.
  59. 59Arora G, et al. Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss. Journal of clinical medicine. 2026;15(2). PMID: 41598480.
  60. 60Jain S, et al. Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS. Reviews in endocrine & metabolic disorders. 2013;14(2):113-8. PMID: 23657561.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.